Cited by 9Fibromyalgia and Chronic Fatigue Syndrome ResearchHealth Systems, Economic Evaluations, Quality of LifeMusculoskeletal pain and rehabilitation

Economic and humanistic burden of fibromyalgia in the USA

Evans, Christopher J, Parthan, Anju, Le, Kim·2006·Expert Review of Pharmacoeconomics & Outcomes Research

Abstract

Fibromyalgia is a complex, chronic condition involving persistent and widespread pain of unknown origin. In the USA the syndrome affects approximately 2% of the population, with prevalence increasing with age, and has a greater predominance in females. The results of this review have found that there is a considerable economic burden associated with this disease, and in particular, the effect of the syndrome on economic losses associated with work activities is at least as important as direct medical costs. The humanistic burden is more difficult to quantify due to the numerous symptoms associated with this disease: widespread pain, persistent fatigue, feeling of weakness, sleep disturbances, morning stiffness, bowel and bladder irritability, mood disturbances, cognitive difficulties, dyesthesia/parethesia, chronic rhinitis, palpitations, auditory/vestibular/ocular complaints, regional pain and joint swelling. Overall, additional research is needed to quantify the impact of fibromyalgia on sufferers in the USA and the cost-effectiveness of alternative treatment strategies.

Integrity signals

Registry

Crossref · 10.1586/14737167.6.3.303

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Evans, C. J., Parthan, A., & Le, K.
Affiliations
Eli Lilly (United States) (US)
Venue
Expert Review of Pharmacoeconomics & Outcomes Research
Published
2006-06
Volume
6
Issue
3
Pages
303-314
ISSN
  • 1473-7167 (ISSN-L)
  • 1744-8379
OpenAlex
W2160514645
Cited by
9
References
56
Citations by year
2026: 1 · 2020: 2 · 2015: 1 · 2014: 1 · 2013: 1
FWCI
0.42
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Review of Pharmacoeconomics & Outcomes Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Pharmacology › Musculoskeletal pain and rehabilitation
Keywords
fibromyalgia, economic burden, humanistic burden, work productivity loss, health care costs, chronic widespread pain, fatigue, sleep disorders, mood disturbance, cognitive difficulties, cost-effectiveness, treatment options

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review